In consonance, impairment of insulin and glucose metabolism by ERβ has significant implications for our understanding of hormone receptor-dependent pathophysiology of metabolic diseases, and is essential for the development of new ERβ-selective agonists. The gene discussed is ESR2; the disease is metabolic disease.